Perceptive Advisors Llc Sells 3,400,000 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the firm’s stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total transaction of $4,828,000.00. Following the transaction, the insider now owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. This trade represents a 36.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aldeyra Therapeutics Trading Down 1.5 %

NASDAQ:ALDX opened at $1.92 on Wednesday. The firm has a 50-day moving average price of $5.81 and a 200 day moving average price of $5.36. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. Aldeyra Therapeutics, Inc has a 12-month low of $1.14 and a 12-month high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30). Equities research analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

ALDX has been the subject of a number of research analyst reports. BTIG Research reduced their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, April 4th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Aldeyra Therapeutics during the fourth quarter worth about $3,628,000. State Street Corp lifted its position in Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after acquiring an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after purchasing an additional 295,864 shares during the period. Barclays PLC boosted its position in shares of Aldeyra Therapeutics by 280.1% in the third quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after acquiring an additional 48,313 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of Aldeyra Therapeutics by 14.4% during the 4th quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,822 shares in the last quarter. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.